Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late, which are much ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...

Hers provides medications for weight loss, hair loss, mental health, sexual health, and more. Here’s the lowdown on how it works and what it costs. Share on Pinterest Hers, a part of the Hims ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...

Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...